Q-omics provides the consensus-scored RN7SL403P profile across patient tissues and cancer cell-line models. RN7SL403P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RN7SL403P is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, RN7SL403P RNA expression shows 17,610 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, THCA, and THYM as cancer lineages where RN7SL403P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL403P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL403P survival associations across molecular data types. RN7SL403P RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL403P RNA expression–survival associations across cancer types. High RN7SL403P expression shows unfavorable associations in LGG, UCEC and LIHC, but favorable associations in LUAD, READ and UCS. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for RN7SL403P RNA expression.
This table summarizes RN7SL403P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL403P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL403P shows lower tumor expression in THCA, BRCA, KICH, KIRP, KIRC and UCEC. The THCA box plot shows higher RN7SL403P RNA expression in normal versus tumor tissue (log2 FC = −0.302, t-test p < 0.001).
This table shows molecular features associated with RN7SL403P in patient tissues and cancer cell lines. In patient samples, RN7SL403P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
